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Abstract Modulating PI3K at different stages of dendritic cells (DC) generation could be a novel means to balance the
generation of immunosuppressive versus immunostimulatory DC. We show that PI3K inhibition during mouse DC gen-
eration in vitro results in cells that are potently immunosuppressive and characteristic of CD8alpha- CD11c? CD11b?
DC. These DC exhibited low surface class I and class II MHC, CD40, and CD86 and did not produce TNF-alpha. In
allogeneic MLR, these DC were suppressive. Although in these mixed cultures, there was no increase in the frequency of
CD4? CD25? Foxp3? cells, the Foxp3 content on a per cell basis was significantly increased. Sustained TLR9 signaling
in the presence of PI3K inhibition during DC generation overrode the cells’ suppressive phenotype.
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Introduction
Many studies indicate that the PI3K pathway is an
important point of regulation of immune cell activation and
function in innate immunity [1–3]. While most reports
indicate that the PI3K pathway is instrumental in cell
survival, prevention of apoptosis, proliferation, B- and
T-cell receptor signaling as well as chemotaxis in many
immune cells, this signaling pathway can also control the
production, accumulation, and binding of transcription
factors required for the expression of critical proinflam-
matory cytokines like IL-12 and immunosuppressive
cytokines like IL-10 [4–8]. Once activated, PI3K signals
mainly via Akt with multiple downstream targets that
include the mammalian target of rapamycin (mTOR),
glycogen synthase kinase-3 beta (GSK-3 beta), and fork-
head box O (FoxO) transcription factors [3, 9–11]. PI3K is
also important in the control of DC maturation and survival
[3, 9–12]. A number of studies demonstrate that PI3K is
important in the development and differentiation of human
DC in vitro [4, 7, 11, 13–16] even though its precise role at
discrete points during DC development is unclear.
The role of PI3K in innate immunity has raised ques-
tions about its importance in acting as a safety mechanism
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in controlling the strength of immune responses to patho-
gens [17]. Modulating its activity could affect the pheno-
type of innate immune cells in vivo as well as during their
in vitro generation from progenitors. PI3K modulation in
dendritic cells (DC) for example could determine a balance
in whether they adopt an immunostimulatory or an immu-
nosuppressive state. In DC, PI3K is activated by LPS,
peptidoglycan, CD40 ligand, RANK ligand, and CpG oli-
gonucleotides, all which result in DC production of IL-12
[17]. Also, PI3K is activated following stimulation of many
of the characterised toll-like receptors (TLRs) [17]. While
most of the TLR signals in DC are proinflammatory, some
studies indicate that TLR9 can act, under certain circum-
stances, to induce immunosuppressive activity in DC [17].
TLR9 activates p38 MAP Kinase (p38) which is one of the
main pathways culminating in nuclear translocation and
activity of NF-kappaB in DC [3, 8, 18–20]. However,
TLR9 can also signal through PI3K [3, 8, 18–20]. Indeed,
PI3K can regulate p38 [1–3, 8–11, 15–22], and such a
mechanism could underlie TLR9 effects on the mainte-
nance or shift of DC activity toward immunosuppression.
Dendritic cells are the body’s sentinels largely responsi-
ble for host surveillance against microenvironmental anom-
alies including pathogen invasion, infection, and damaged
tissue architecture, while coordinating the mechanisms of
self-tolerance [23–26]. They have become very attractive
candidates, in recent years, for tumor and antiviral immu-
notherapy [27–30]. Depending on the methods used to gen-
erate DC from monocyte progenitors present in human
PBMC, or bone marrow progenitors from mice, the outcome
can be a population of cells that potently activate the immune
system against pathogens and tumors, or cells that can induce
antigen-specific immune hyporesponsiveness and even tol-
erance [31, 32]. Many lines of investigation show that DC in
a functionally immature state (characterised by low to absent
co-stimulatory molecules) are powerful agents of immune
hyporesponsiveness [25, 33]. Exogenous administration of
functionally immature DC achieves long-term and stable
allograft survival in a variety of mouse and rat models and
prevents a number of autoimmune diseases [34–38]. Mech-
anistically, functionally immature DC act by inducing
anergy either via direct cell contact and/or altering cytokine
production inside the lymphoid organs [33, 39, 40]. Fur-
thermore, as described more recently, DC rendered tolero-
genic can directly upregulate the number and function of
regulatory immune cell subsets, especially antigen-specific
CD4? CD25? Foxp3? T-cells as well as a class of CD8?
immunosuppressive T-cells [41–49]. Some studies addi-
tionally suggest that tolerogenic DC could also act by
degrading tryptophan in the local environment, following the
upregulation of the key metabolising enzyme IDO [50–52].
The generation of DC for immunotherapy in rodent
models or humans mostly relies on the inclusion of
GM-CSF and IL-4 in the culture medium [53–62]. Very
little is known about the molecular pathways active in DC
during this culture period that could potentially be
exploitable to shift the developmental balance in favor of
an immunostimulatory or immunosuppressive DC product.
We have begun an investigation into the intracellular
pathways active and altered during the generation of DC in
vitro. As a first approach, we focused on the signaling in
mouse DC developing from bone marrow progenitors. We
have discovered that the PI3K pathway can be an important
regulator in determining whether GM-CSF/IL-4-cultured
DC progenitors differentiate into DC with immunosuppres-
sive or immunostimulatory capacity. Furthermore, we have
also demonstrated that TLR9 signaling during the generation
of PI3K-impaired DC overrides their suppressive capacity.
Interestingly, we also discovered that initiation of PI3K
inhibition after DC generation in vitro cannot confer an
immunosuppressive capacity to DC and that TLR9 signaling
potentiates the stimulatory phenotype of DC rendered PI3K-
impaired post-generation in vitro. Our data suggest that PI3K
inhibition during the generation period yields immunosup-
pressive DC resembling CD8alpha- CD11c? CD11b?
cells while PI3K inhibition post-generation promotes immu-
nostimulatory DC whose activity is potentiated by TLR9 sig-
naling. At the signaling level, we uncovered a dynamic and
complex interplay between the phosphorylation of p38 and
GSK-3 beta during DC generation in vitro.
Materials and methods
Biochemicals
The PI3K inhibitor LY-294002 was purchased from Cal-
biochem (EMD Chemicals, Gibbstown, NJ) as an ultrapure
powder and reconstituted in DMSO and reconstituted for
use in cell culture in endotoxin-free sterile PBS. Cell culture
reagents (media and sera) were all purchased from Invit-
rogen (Carlsbad, CA). CpG oligonucleotide ODN 1826
[63–66] was synthesised to high purity with undetectable
levels of endotoxin by IDT technologies (San Diego, CA).
All other biochemicals and reagents were purchased from
Sigma, BioRad or Invitrogen unless otherwise indicated.
Animals
C57BL/6 and Balb/c mice were purchased from Jackson
Laboratories (Bar Harbor, ME). All animals were kept
under specific pathogen-free conditions. Bone marrow and
spleen were collected from 8- to 10-week-old mice. Animal
care and all procedures were performed in accordance with
institutional (University of Pittsburgh DLAR and IACUC),
state and federal guidelines.
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Generation of dendritic cells
Dendritic cells were generated from bone marrow pro-
genitors obtained from C57BL/6 mice in 6-day cultures
with GM-CSF and IL-4 using previously published proto-
cols [67, 68] in the continuous presence or absence of LY-
294002 (25 micromolar final concentration) and/or CpG
ODN 1826 (0.5 micromolar final concentration). DC gen-
erated in cultures with only GM-CSF and IL-4 served as
controls. Parallel DC were generated for 6 days in the
presence of GM-CSF and IL-4 alone, GM-CSF/IL-4 and
LY-294002, GM-CSF/IL-4 and ODN 1826, or GM-CSF/
IL-4 and LY-294002/ODN 1826. Culture supernatants and
cells were collected on day seven for all further studies. In
some experiments, the PI3K inhibitor LY-294002 with or
without ODN 1826 was added in GM-CSF/IL-4-generated
DC at the end of the 6-day culture period (after the GM-
CSF/IL-4 DC generation period). Supernatants and cells
from these cultures were collected 24 h after the addition
of the PI3K inhibitor/ODN 1826.
Phosphoprotein determination, Western blotting,
and data analysis
Whole, cytoplasmic, and nuclear protein extracts from DC
collected at the times illustrated above were obtained using
NER-PER or M-PER protein extraction reagents as
appropriate (Pierce Biotechnology). Protein concentration
was determined by the BCA Protein Assay Kit (Pierce) and
standardised to bovine serum albumin. Nuclear (10 lg),
cytoplasmic (10 lg) or whole protein lysates (40–60 lg)
from the DC were separated in 10% SDS–PAGE, electro-
transferred onto a PVDF membrane (BioRad) and incu-
bated with specific antibodies to the indicated intracellular
signaling molecules (p38 MAP Kinase, Akt, NF-kappaB
p65, GSK-3beta as well as their signaling-related phospho-
specific antibodies (NFkB p65 (C20) sc-372 Santa Cruz
Biotechnology; Akt, 9272, Cell Signaling; p-Akt (Ser 473)
9271, Cell Signaling; GSK-3b (11B9) sc-81462, Santa
Cruz Biotechnology; p-GSK-3b (Ser 9) 9336, Cell Sig-
naling; p38 MAP Kinase (N20) sc-728, Santa Cruz Bio-
technology; p-p38 MAP Kinase (Tyr 182) sc-7975-R,
Santa Cruz Biotechnology; ERK (K23) sc-94, Santa Cruz
Biotechnology; b-actin, 5441, Sigma) followed by incu-
bation with horseradish peroxidase (HRP)-conjugated
secondary antibody (HRP-conjugated Rabbit anti Goat
IgG, 305-035-003, Jackson ImmunoResearch Labs; HRP-
conjugated Goat anti Rabbit IgG, 111-035-047, Jackson
ImmunoResearch Labs; HRP-conjugated Goat anti Mouse
IgG, 31430, Pierce). Protein–antibody complexes were
visualised by enhanced chemiluminescence with the GE
Healthcare ECL system.
Immune cell isolation, allogeneic mixed leukocyte
reaction (MLR), fluorescence-activated cell sorting
(FACS), flow cytometry, and cytokine detection/
measurement
T-cells were prepared from freshly isolated splenocytes of
C57BL/6 mice. CD4? or CD4? CD25? T-cells were
purified using the CD4? T-cell isolation columns (R&D
Systems) or a specific CD4? CD25? isolation kit as per
the manufacturer’s recommendations (Miltenyi Biotec).
These cells were maintained in RPMI 1640 medium sup-
plemented with 10% fetal bovine serum, 50 micromolar
beta mercaptoethanol, 1% sodium pyruvate, and 1% non-
essential amino acids (all purchased from Invitrogen).
For MLR to determine the capacity of the DC for all-
ostimulation in vitro, 2 9 105 CD4? T-cells from alloge-
neic Balb/c mice were co-cultured with an equal number of
irradiated DC from bone marrow progenitors of C57BL/6
mice (DC generated from cultures as described earlier) for
a period of 5 days in RPMI with 10% FBS. At the end of
incubation, 10 micromolar BrdU was added for the final
16 h to assess proliferation. T-cell proliferation was
determined by the level of FITC fluorescence and % cells
fluorescent by FACS analysis using the FITC-BrdU flow
cytometry kit (BD Pharmingen).
The frequency of CD4? CD25? Foxp3± cells in the
MLR co-cultures was measured by fluorescence-activated
cell sorting analysis (FACS) following the 6-day DC
generation period or the time after the addition of the PI3K
inhibitor/ODN 1826 in differentiated DC. Cells were
removed from the plastic multiwell plates and stained with
antibodies specific for CD4, CD25, and Foxp3 (CD4, clone
GK1.5, BD Biosciences; CD25, clone 7D4, BD Biosci-
ences; Foxp3, clone FJK-16s, eBiosciences). The fluoro-
phores on the antibodies were complementary with distinct
emission spectra so that no bleeding or overlap would
occur during FACS analysis. Antibody-specific isotypes
were used throughout to exclude non-specific staining.
Luminex-based multianalyte assays using commercially
purchased systems (Beadlyte Assay System, Upstate Bio-
technology) were performed on culture supernatants (DC
alone, or MLR supernatants) to profile cytokine produc-
tions and levels of each cytokine. All measurements were
performed in duplicate from triplicate DC cultures on at
least two occasions.
Statistical analyses
ANOVA and the Student’s t test in Graph Pad Prism ver-
sion 4.0 were used to determine statistical significance in
the measurements among the different DC treatment
groups and the biologic responses in the presence or
absence of the PI3K inhibitor with or without ODN 1826.
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A P value of less than 0.01 among the means was
considered statistically relevant.
Results
DC generated in the presence of a PI3K inhibitor
exhibit a morphologically immature phenotype
with decreased CD11c expression
It is well known that immature DC are metastable cells that
can be manipulated toward immunosuppressive or immu-
nostimulatory capacity in vitro [25, 31, 69, 70]. The sig-
naling pathways inside their hematopoietic progenitors and
how they change during DC generation in vitro are not
completely known, although data are emerging demon-
strating an important role of the PI3K pathway [11, 71–74].
A number of studies indicate that PI3K could be modulated
during DC generation and that, depending on its activity,
the balance in favor of generating immunosuppressive or
immunostimulatory DC could be altered [3–5, 9, 11, 12,
14, 17, 21, 73, 75].
To determine the effects of PI3K inhibition during the
generation of DC from bone marrow progenitors on the
morphological maturity of the DC, we stained day 6
DC (control and those generated in the presence of
LY-294002) with DAPI and a FITC-conjugated CD11c
antibody. In Fig. 1, we show that control DC are larger in
diameter and suggestive of a larger volume compared to
PI3K-impaired DC. The density of CD11c on the PI3K-
impaired DC was considerably less than that on control
DC. Overall, the morphology of the DC generated in the
presence of LY-294002 was reminiscent of immature DC
[59, 76, 77].
PI3K inhibition can affect cell viability. We determined
whether PI3K inhibition, using the specific pharmacologic
inhibitor LY-294002 [16, 74, 78–80] during the process of
murine DC generation from GM-CSF/IL-4-cultured bone
marrow progenitors, induced apoptotic and/or necrotic
events in the differentiating cells in vitro. We measured
viability and apoptosis onset in control or LY-294002-
supplemented GM-CSF/IL-4 DC cultures by propidium
iodide (PI) and Annexin V staining at the end of 6-day
cultures (standard protocol for generating murine DC in
vitro; [59]). In Fig. 1, we show that less than 10% of
the total cells in culture at day 6 are PI- and Annexin
V-co-positive (graph and representative FACS plots).
Furthermore, there are no differences in PI staining or
Annexin V staining between control and LY-294002-trea-
ted DC. Routinely, by day 6, we obtain about 2 9 106
CD11c? DC from 3 9 107 bone marrow progenitors
[59, 76, 77]. We did not observe any significant differences
Fig. 1 LY-294002-generated DC exhibit a morphologically imma-
ture phenotype in vitro. DC generated in GM-CSF/IL-4 cultures in the
presence or absence of LY-294002 were stained with a FITC-labeled
anti-CD11c antibody and then counterstained with DAPI. The panels
represent fluorescence of CD11c? cells (green) and the DAPI-stained
nuclei (blue) in cytospins. We show cells at 940 magnification. The
low levels of FITC in the LY-294002-generated DC indicate an
immature state. The FACS quadrants below the immunofluorescence
images are representative of the accumulation of propidium iodide
(PI; y-axis) and Annexin V staining (x-axis) of day 6 DC (control and
LY-294002-generated). The graph summarises the degree of apop-
totic/necrotic cells with the bars indicating the means of triplicate
cultures and the error bars the SEM. There were no significant
differences in apoptotic/necrotic cells under control or LY-294002
conditions
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in the yield of CD11c? DC when LY-294002 was included
in the cultures (data not shown).
PI3K inhibition during the generation of DC
from murine bone marrow progenitors confers
immunosuppressive capacity in allogeneic MLR
in vitro
Based on the morphology of the LY-294002-generated DC
in vitro, we proposed that the immature phenotype could
extend to their functional capacity in affecting allore-
sponses in vitro. To directly test this possibility, we
established standard 5-day MLR co-cultures with irradiated
control DC or LY-294002-generated DC and an equal
number of splenic T-cells from allogeneic mice (2 9 105
DC:2 9 105 T-cells). At the end of the MLR, we collected
the supernatants of the multiwell plates and measured
proliferation of cells using flow cytometry-based ascer-
tainment of BrdU incorporation as described in the
‘‘Materials and methods’’ section. In Fig. 2, we show that
LY-294002-generated DC were unable to stimulate the
proliferation of allogeneic T-cells beyond the basal pro-
liferation seen in wells with the T-cells alone.
DC generated in the presence of a PI3K inhibitor
exhibit features similar to immunoregulatory
CD8alpha- CD11c? CD11b? DC
along with decreased cell surface CD40 and CD86
co-stimulatory proteins
Using LY-294002-generated DC in MLR, the proliferation
of allogeneic T-cells was impaired and suggested a number
of possible mechanisms including: (1) low levels of MHC
on the DC surface; (2) poor provision of costimulation by
the PI3K-impaired DC; (3) production of immunosup-
pressive cytokines by the DC or by the T-cells in the MLR
co-cultures; (4) a shift in the phenotype of the responsive
T-cells (TH1 to TH2); or (5) the activation/proliferation of
adaptive Foxp3? Tregs in the MLR that could suppress the
proliferation of non-regulatory T-cells. To determine which
of these mechanisms could underlie the hyporesponsive-
ness conferred by the LY-294002-generated DC, we first
measured the levels of class I (H-2d and H-2K) and class II
(I-Ab) molecules on the surface of CD11c? CD11b? cells.
DC generated in the presence of LY-294002 clearly exhib-
ited significant decreases in class I and II MHC (bottom
panels in Fig. 3a) in CD11c? CD11b? and CD11c?
CD11b- cells. Interestingly, the distribution of CD11c and
CD11b changed significantly in pattern in LY-294002-
generated DC (top panels in Fig. 3a). By FACS analysis,
control-generated DC segregated into four distinguishable
populations along the lines of CD11c and CD11b (top left
panel, Fig. 3a), whereas LY-294002-generated DC segregated
into two readily distinguishable populations, the majority
of cells exhibiting a CD11c?/HIGH CD11bINTERMEDIATE
surface phenotype (top right panel, Fig. 3a).
We then measured the frequency of CD86?, CD80?,
and CD40? DC as well as the relative cell surface expres-
sion of these three important co-stimulatory proteins by
flow cytometry. In Fig. 3b, we show that generation of
murine bone marrow DC in the presence of LY-294002
results in significant suppression of CD40 and CD86 on the
cell surface of the DC compared to that on control DC
during the generation period, in vitro (determined as mean
fluorescence intensity of the cell surface protein by FACS
analysis). In the same figure (right-side panel), we show
that the frequency of CD86? and CD40? DC in cultures
generated in the presence of LY-294002 is significantly
lower than in cultures of control DC. These data suggest
Fig. 2 LY-294002-generated DC suppress allostimulation of T-cells
in mixed leukocyte culture in vitro. Irradiated control or LY-294002-
generated DC were co-cultured at an equal ratio of DC:T-cells for
5 days. The T-cells were enriched from the spleen of an allogeneic
mouse strain. At the end of the incubation, the supernatants were
collected, and the cells were further cultured in the presence of BrdU.
After an overnight incubation in BrdU, the cells were collected and
processed to measure the frequency of BrdU? cells (representing
proliferating cell frequency) by FACS. The graph shows the
frequency of proliferating cells as a stimulation index (SI). The SI
was calculated by dividing the proliferation of T-cells in the different
co-cultures (or the DC alone) by background proliferation. Prolifer-
ation observed in cultures of T-cells only was considered to be the
background level and assigned a value of 1. The error bars represent
the SEM of quadruplicate wells. P \ 0.0001 by Student’s t test
comparing proliferation of allogeneic T-cells in co-culture with
control-generated DC compared to LY-294002-generated DC
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that LY-294002 acts at least at two levels in the generation
of immature DC in vitro: first, it suppresses the frequency
of DC in vitro that differentiate into cells with significant
expression of CD40 and CD86 at the cell surface; and
second, it suppresses the level of these two co-stimulatory
proteins on the surface of DC on a per cell basis. We did
not observe any differences in CD80 relative cell surface
levels or frequency of CD80? cells in DC cultures
generated in the presence of LY-294002 compared to
control conditions.
The segregation of control and LY-294002-generated
cells into CD11c? and CD11b?/INTERMEDIATE populations
suggested the possibility that some of these cells could be
CD8alpha- suppressive DC [81–83]. In Fig. 3c, we show
that such CD8alpha- cells reside inside the CD11c?
CD11b? population in control-generated DC (left-side
panel). LY-294002-generated DC do not exhibit any sig-
nificant changes in the frequency of CD8alpha- CD11c?
CD11b? cells; however, most of the CD8alpha- cells
segregate outside the CD11bHIGH CD11c? population and
into a CD11bINTERMEDIATE CD11c? population (right-side
panel, Fig. 3c).
Cytokine profiles in supernatants of LY-294002-treated
DC cultures
Co-stimulation impairment has been shown to underlie
many instances of DC-directed hyporesponsiveness of
allogeneic and autoimmune T-cell proliferation in vitro and
in vivo [25, 70, 84, 85]. However, changes in cytokine
production by DC are also known to provide additional
levels of control of T-cell proliferation [86–90]. We first
determined the profile of cytokines produced, as well as
their concentration, in the culture supernatants of bone
marrow progenitors differentiating toward DC in the
presence of LY-294002 or PBS vehicle.
By Luminex assay, we did not detect any of the classical
TH1-type cytokines in unstimulated control-generated DC
or LY-294002-generated DC (data not shown). We then
ascertained the cytokine profile and measured the cytokine
levels in the supernatants of the allogeneic MLR referred to
earlier (shown in Fig. 2). We identified differences in the
concentrations of cytokines in DC generated in the pres-
ence of LY-294002 compared to control DC (Fig. 4;
increased GM-CSF, increased IL-13, decreased IL-5,
undetectable TNF-alpha, undetectable MCP-1,). Although
these changes are suggestive of a shift of T-cell populations
toward a state of regulatory capacity, they are not a clear
cut and well-defined TH1-to-TH2 shift [91–94]. Indeed, we
did not detect any significant levels of IL-1-beta, IFN-
gamma, IL-4, or IL-10 in the MLR supernatants nor were
there any real differences between MLR co-cultures with
control and PI3K-impaired DC (not shown).
PI3K-impaired DC promote a decrease in the frequency
of CD4? CD25? Foxp3- cells in vitro in mixed
culture
The differences in cytokine profiles of MLR-derived
supernatants between co-cultures with control DC and LY-
294002-generated DC suggested that another potential
Fig. 3 a LY-294002-generated DC segregate into CD11c- CD11b?
and CD11c? CD11b± population with significantly lower levels
of class I and class II MHC on a per cell basis compared to
control-generated DC in vitro. Compared to the segregation of
control-generated DC, LY-294002-generated DC segregate into two
populations, a major CD11c? CD11b± and a minor CD11c-
CD11b? population. The illustrations at the right side of the FACS
quadrants in the top panels indicate the % of day 6 bone marrow-
derived cells segregating into each of the quadrants representing
CD11c and CD11b. The lower panels illustrate the mean fluorescence
intensity (MFI) of class I and class II MHC on the cells segregating
into each of the four quadrants representing CD11c and CD11b. The
lower left panel illustrates MHC MFI on control-generated cells, and
the right lower panel illustrates MHC MFI on LY-294002-generated
cells. These data represent the measurement of FACS analysis means
and SEM of triplicate independently generated cultures in vitro.
b Continuous LY-294002 presence in GM-CSF/IL-4 DC generation
cultures from murine bone marrow progenitors decreases the frequency
of CD40? and CD86? DC as well as a decrease in the level of CD40
and CD86 on a per cell basis in vitro. By measuring the frequency of
CD40? and CD80? cells on each of the days of the 6-day DC
generation process, the degree of maturation of LY-294002-generated
DC, determined by the % of CD86? and CD40? cells, was
discovered to be less than control-generated DC (right-side panel).
The data are representative of three separate DC generations under the
defined conditions. The values below the graph show the frequency of
CD40? or CD86? cells (% of cells in a gate of high forward and high
side scatter cells, ascertained by FACS) measured on that day.
Control indicates DC generated under standard GM-CSF/IL-4 proce-
dure (refer to ‘‘Materials and methods’’), and LY represents DC
generated in the continuous presence of LY-294002. We also
measured the mean fluorescence intensity (MFI) of CD86 and
CD40 by FACS. The graphs (left-side panel) show the MFI of each
co-stimulatory protein on cells collected at each of the days. The
values below the graph show the specific MFI measured on that day.
Control indicates DC generated under standard GM-CSF/IL-4 proce-
dure (refer to ‘‘Materials and methods’’), and LY represents DC
generated in the continuous presence of LY-294002. The data are
representative of three separate DC generations under the defined
conditions. c CD8alpha- CD11c? CD11b? DC are generated under
control and LY-294002 exposure in vitro with a shift of CD8alpha-
cells into a CD11c? CD11b?/INTERMEDIATE population under
LY-294002 conditions in vitro. The panel on the left shows the
segregation of DC along CD11c and CD11b surface expression.
CD8alpha- cells are distributed between CD11c?
CD11bINTERMEDIATE and CD11c? CD11bHIGH populations. Under
LY-294002 exposure, the frequency of CD8alpha- cells in the
CD11c? CD11bHIGH population significantly decreases and is
redistributed among CD11cINTERMEDIATE CD11bINTERMEDIATE cells
(right-side panel). The values above the histograms represent the
frequency of CD8alpha- cells inside the respective CD11c CD11b
populations referred to in the FACS quadrants as a percentage of the
total gated cells. The values show the mean ± SEM of triplicate
independently generated DC cultures. The FACS quadrants and
histograms are representative of the triplicate cultures
b
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mechanism of impaired T-cell proliferation could involve
increased regulatory T-cell frequency or changes in the
frequency of activated non-regulatory T-cells. Toward this
objective, we measured the frequency of CD4? CD25? as
well as CD4? CD25? Foxp3? cells in the co-cultures at
the end of the 5-day incubation period of freshly isolated
splenic T-cells and DC generated in the presence or
absence of LY-294002 (Fig. 5). In Fig. 5b, we show that
compared to co-cultures with control DC, LY-294002-
generated DC induced a decrease in the frequency of
CD4? CD25? Foxp3- cells (i.e. active immunocompe-
tent T-cells). In Fig. 5c, we demonstrate that control DC
elicit a significant decrease in the frequency of naive
CD4? CD25- Foxp3- cells while LY-294002-generated
DC induce a dramatic increase in the frequency of the same
naive T-cell population (CD4? CD25- Foxp3- cells). We
did not observe any differences in the frequency of regu-
latory, immunosuppressive CD4? CD25? Foxp3? cells in
cultures where the DC were generated under control or LY-
294002 conditions (data not shown). However, in those
cells that did express Foxp3, we observed that control DC
induce a decrease in the Foxp3 content on a per cell basis
(measured indirectly by FACS in the form of mean fluo-
rescence intensity; MFI) whereas in contrast, LY-294002
DC-co-cultured T-cells expressing Foxp3 exhibit a signif-
icant increase in the content of Foxp3 on a per cell basis
(Fig. 5d). Given that the frequency of CD4? CD25?
Foxp3? cells was not different between control and LY-
294002-generated DC:T-cell co-cultures, the difference in
Foxp3 content on a per cell basis very likely reflects
transcriptional or post-transcriptional mechanisms of
Foxp3 modulation by control and PI3K-impaired DC.
TLR9 signaling promotes immunostimulatory DC
generation in vitro, even in the presence of PI3K
inhibition
At this point, our data suggested that PI3K inhibition
facilitates the generation of immature immunosuppressive
DC in vitro. The PI3K pathway is one point of convergence
Fig. 3 continued
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of TLR signals [14, 17, 20, 72, 79, 95–98]. TLR signaling
often confers immunostimulatory properties to DC, and a
class of DC-based vaccines in clinical consideration are in
essence DC generated in the presence of, or treated at the
end of culture with, CpG oligonucleotides which act via
TLR9 [19, 63, 64, 99]. We asked whether TLR9 activation
using CpG oligonucleotides would override the effect of
PI3K inhibition and shift the balance in favor of generation
of immunostimulatory DC. We repeated the experiments
above; however, this time, we generated DC in the pres-
ence of LY-294002 and oligonucleotide 1826 (ODN 1826)
which is one of the ‘‘classic’’ TLR9 agonists [63–66]. As
controls, we also considered DC generated in the presence
of ODN 1826 alone.
Generation of DC in the presence of ODN 1826
resulted in a segregation of cells into mostly CD11c?
CD11b-/INTERMEDIATE cells with a heterogeneous distri-
bution among CD11c and CD11b (Fig. 6a). A significant
reduction in CD8alpha- CD11c? CD11b? cells was
observed, and the levels of class I and class II MHC were no
different between ODN 1826-generated DC and control-
generated DC (refer to tables at the right side of Fig. 6a).
When the DC were generated in the presence of LY-294002
and ODN 1826, at the end of the generation period, the cells
segregated mainly into CD11c?/HIGH CD11bHIGH and a
CD11c- CD11b- population. The largest distribution was
into the CD11c?/HIGH CD11bHIGH population (Fig. 6a
bottom panel). The resemblance of these cells to control-
generated DC and the low levels of class I and class II MHC
suggested that they may exhibit functionally suppressive
properties in allogeneic MLR in vitro. However, in Fig. 6b,
we show that DC generated in the concurrent presence of the
PI3K inhibitor and ODN 1826 are as stimulatory as in
co-cultures where the DC were not treated during the gener-
ation period or where the DC were generated in the presence of
the DC immunostimulatory CpG ODN 1826. In support of
these data, we observed that IL-1 beta and IL-6 were signifi-
cantly increased in MLR supernatants from co-cultures of
T-cells with DC generated in the presence of ODN 1826
(Fig. 6c). Although the generation of DC in the co-presence of
ODN 1826 and LY-294002 elicited greater IL-1 beta pro-
duction compared to ODN 1826 alone, IL-6 production was
not as responsive to DC generated in the co-presence of
ODN1826 and LY-294002 compared to co-cultures with DC
treated only with ODN1826, suggestive of a suppressive
effect of PI3K inhibition on the production of IL-6.
Effects of PI3K inhibition during the generation of DC
from murine bone marrow progenitors on Akt, p38,
and nuclear GSK-3 beta phosphorylation as well
as NF-kappaB p65 nuclear accumulation in vitro
To gain an understanding of the signaling pathways that
PI3K inhibition could affect in DC during the generation
Fig. 4 Cytokine profile of supernatants from mixed leukocyte
cultures of LY-294002-generated DC exhibits an immunoregulatory
TH2-like phenotype. Luminex multi-analyte assay was used to
measure the concentration of 22 cytokines, chemokines, and growth
factors in day 5 supernatants of the mixed leukocyte reactions shown
in Fig. 2. Suppression of TNF-alpha and MCP-1 with concomitant
upregulation of IL-13 is suggestive of T-cells producing cytokines
that would promote a TH2-like state of immune environment. The
graphs show the concentrations of each of the detectable cytokines,
and the error bars represent the SEM of quintuplicate wells. The data
are representative of at least two independent experiments
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process, we performed Western blots to determine the
phosphorylation state of PI3K downstream target Akt, p38,
nuclear GSK-3 beta as well as the nuclear accumulation of
NF-kappaB p65. GSK-3 beta was of particular interest
given the evidence that it can modulate IL-10 expression in
antigen-presenting cells and of the role of DC-derived
IL-10 in immunoregulation [100].
In Fig. 7a, we demonstrate the absence of phosphory-
lated Akt in differentiating DC in the presence of
LY-294002 during all 6 days, whereas control DC exhib-
ited phosphorylated Akt on all days (although from day 4
onward, there appears to be a slightly decreased level of
phosphorylation). The absence of phosphorylated Akt in
DC generated in the presence of LY-294002 is an expected
Fig. 5 LY-294002-generated DC elicit a decrease in the frequency of
CD4? CD25? Foxp3- cells and an increase in CD4? CD25-
Foxp3- cells while slightly upregulating the level of Foxp3 in
existing, but not proliferating CD4? CD25? Foxp3? T-cells in
mixed leukocyte reaction in culture. At the end of the 5-day MLR
shown in Fig. 2, parallel co-cultures were stained with fluorescent
antibodies specific for CD4, CD25, and Foxp3. The frequency of cells
was measured by FACS. All graphs show the frequency of the cell
population indicated on the y-axis of each graph and the error bars
the SEM of quadruplicate wells. a The quadrants show the FACS
gating criteria used to measure the frequency of the indicated cells.
LY-294002-generated DC induce a shift in the population frequency
of CD4? CD25HIGH Foxp3- cells into a population of CD4?
CD25LOW/NEGATIVE Foxp3- cells (from quadrant 1–6 into quadrant
3–6). b Co-culture of LY-294002-generated DC with allogeneic
T-cells results in a decrease in the frequency of CD4? CD25?
Foxp3- T-cells. P \ 0.05 (LY-294002 DC vs. control DC:T-cell co-
cultures, Student’s t test). c Although co-culture of control DC-
generated DC with allogeneic T-cell elicited a decrease in CD4?
CD25- Foxp3- T-cells, LY-294002-generated DC induced a
significant increase in the frequency of this T-cell population.
P \ 0.01 (LY-294002 DC vs. control DC:T-cell co-cultures, Stu-
dent’s t test). d Control-generated DC induced a significant decrease
in the level of Foxp3 in CD4? CD25? Foxp3? cells (that did not
exhibit any differences in frequency compared to cultures with T-cells
alone), but LY-294002-generated DC elicited an increase in Foxp3
levels in CD4? CD25? Foxp3? T-cells. P \ 0.01 (LY-294002 DC
vs. control DC:T-cell co-cultures, Student’s t test)
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result and confirms the inhibition of PI3K using LY-
294002.
We then looked at the phosphorylation of p38 MAP
Kinase (p38), an important signal transducer during DC
maturation which is also phosphorylated and activated in
response to external proinflammatory triggers [8, 101–
104]. While a low, apparently basal level of phosphory-
lated p38 was evident in control DC on each of the days
during in vitro generation, quite likely reflecting the con-
tinuous effects of culture-supplied GM-CSF signals known
to stimulate p38 [105–108], in Fig. 7b, we show that the
level of p38 phosphorylation in DC generated in the
presence of LY-294002 was elevated.
Dendritic cells generated in vitro normally exhibit
detectable levels of nuclear NF-kappaB and basal NF-
kappaB activity which is important in cell survival and
maintenance of a state where DC facilely take up exoge-
nous molecules and express basal co-stimulatory proteins.
Upon encountering proinflammatory signals, such as TLR
agonists, NF-kappaB nuclear accumulation dramatically
increases, and the transcription of genes important in the
maturation and the capacity to provide co-stimulation to
T-cells is substantially augmented [8, 109, 110]. To
determine whether PI3K inhibition affected NF-kappaB
nuclear levels in differentiating DC, we ascertained the
nuclear levels of NF-kappaB p65 in DC generated under
control conditions or LY-294002. In Fig. 7c, we show that
p65 NF-kappaB is detectable in nuclear extracts of control
and LY-294002-generated DC; however, starting on day 3,
the levels of p65 in LY-294002-generated DC are signifi-
cantly reduced and are apparently maintained at this level
until the end of the generation period (Fig. 7c).
A number of studies indicate that, just like NF-kappaB,
GSK-3 beta is a transcription factor responsive to TLR
signals which can play an important role in shifting an
antigen-presenting cell’s phenotype from that of a potent
immunostimulator to a cell that can induce immunosup-
pression [97, 100, 111, 112]. A number of studies confirm
that GSK-3 beta regulates IL-10 gene expression [100,
113–115], and DC that express IL-10 can shift a T-cell
response from a proinflammatory TH1 to a regulatory TH2
type [116, 117]. Phosphorylation of GSK-3 beta renders it
inactive, whereas the unphosphorylated form is transcrip-
tionally active [118, 119]. It was of interest, therefore, to
establish the co-accumulation pattern of nuclear NF-kap-
paB p65 and phospho-GSK-3 beta in DC generated from
bone marrow progenitors every day during the generation
period under control or LY-294002 conditions. In Fig. 7d,
we show a progressive decline in nuclear phospho-GSK-3
beta levels under control conditions, starting on day 2.
However, in LY-294002-generated DC, we demonstrate a
stable level of nuclear phospho-GSK-3 beta and at levels
higher than DC generated under control conditions.
p38 phosphorylation is suppressed
during the generation of PI3K-impaired DC
in the presence of sustained TLR9 signaling
We then sought to identify the changes in phosphorylation
of the proteins outlined above in DC generated in the
co-presence of LY-294002 and ODN 1826, a well-known
TLR9 agonist. In Fig. 8a, we show that, as expected,
generation of DC in the continuous presence of ODN 1826
alone maintained phospho-Akt to levels similar to those in
control-generated DC. However, phospho-p38 was almost
absent at all days when DC were generated in the contin-
uous presence of ODN 1826 compared to the level in
control DC (Fig. 8a). Nuclear phospho-GSK-3 beta levels
were also increased in DC generated in the presence of
ODN 1826 alone compared to control-generated DC
(Fig. 8b). We show that the levels of phospho-Akt were
barely discernible at all days during DC generation in the
presence of LY-294002 even when ODN 1826 was inclu-
ded for all days compared to control-generated DC
(Fig. 8c). The co-inclusion of ODN 1826 with LY-294002
during the DC generation period resulted in a more pro-
nounced and progressive loss of phospho-p38 compared to
control-generated DC (Fig. 8d). Nuclear phospho-GSK-3
beta levels, in DC generated in the co-presence of LY-
294002 and ODN 1826, were no different than in control
condition-generated DC; however, we believe that this
represents degradation of GSK-3 beta in the LY-294002/
ODN 1826-generated DC and not differences in the
phosphorylation state (compare GSK-3 beta protein levels
between control- and LY-294002/ODN 1826-generated
DC in Fig. 8e).
PI3K inhibition in post-generation DC increases
the immunostimulatory activity of DC in vitro which is
potentiated by a TLR9 agonist oligonucleotide
It is important to note that most of the ex vivo generated
DC for use in human immunotherapy are treated post-
generation (i.e. starting on day 6 or 7 of culture) with
maturation or modulation agents such as TNF-alpha, PGE2,
CpG oligonucleotides [120–122]. We therefore asked
whether adding LY-294002 with or without ODN 1826 in
post-generated DC cultures (i.e. adding the LY-294002
and/or ODN 1826 at the end of the DC generation period;
starting on day 6 in GM-CSF/IL-4-generated DC) would
confer to the DC different immune stimulation capacity as
well as differences in the phosphorylation of the proteins
listed earlier compared to DC generated in the presence of
LY-294002/ODN 1826.
In these experiments, the DC were washed free of the
LY-294002 and/or ODN 1826 prior to transfer to allogeneic
T-cell cultures. Unlike the immunsuppressive character of
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the DC generated in the presence of LY-294002 continu-
ously during the DC differentiation culture protocol, the
cells treated with the PI3K inhibitor beginning on day 6
(post-generation) exhibited an increased capacity to stimu-
late allogeneic T-cell proliferation in vitro (Fig. 9a). Fur-
thermore, we also detected a significant increase in the MLR
supernatant concentrations of TNF-alpha (Fig. 9b) when DC
were treated with LY-294002 post-generation. Co-treatment
of the DC with LY-294002 and ODN1826 beginning at the
end of the GM-CSF/IL-4 generation period potentiated their
stimulatory effect on allogeneic T-cell proliferation (Fig. 9c)
and resulted in an increase in IL-6, IL-12p70, and IL-13
concentrations in the allogeneic MLR supernatants (Fig. 9d).
We did not detect any changes in the frequency of any of
the T-cell populations listed earlier and shown in Figs. 5a–
d (data not shown) compared to co-cultures with control
DC. Last, although the levels of phospho-Akt were barely
detectable, the levels of phosphorylated p38, nuclear
phospho-GSK-3 beta, and nuclear NF-kappaB p65 were
not significantly different in DC treated with LY-294002
on day 6 compared to day 6 control (untreated) DC (data
not shown). The addition of ODN 1826 to these LY-
294002-treated day 6 DC also did not affect the phos-
phorylation of p38 or nuclear GSK-3 beta to any degree
significantly greater than in ODN 1826-treated day 6, post-
generation DC (data not shown).
Discussion
PI3K is an important signaling protein for many cellular
processes. In hematopoietic cells as well as almost all
immune cells, it acts as one key convergence point of
multiple signaling pathways including those for growth
factor receptors, cytokine receptors and pattern recognition
proteins such as the TLRs [1, 11, 21]. From this point of
convergence, PI3K signaling projects to multiple and
interrelated horizontally and vertically integrated intracel-
lular signaling networks, most often in a crosstalk manner.
This crosstalk adds to the complexity toward a complete
understanding of PI3K-specific effects, other than its well-
established effect in promoting the phosphorylation and
subsequent activation of Akt [10, 11, 123]. While PI3K-
Akt signaling has best been associated with cell survival
through its effects in the upregulation of a number of anti-
apoptotic molecules [16, 73, 80, 124, 125], less effort has
been applied to understand its other possible roles, espe-
cially in DC.
In this report, we show that sustained PI3K inhibition in
bone marrow progenitors differentiating toward DC under
the effects of GM-CSF and IL-4 results in the generation of
immature, immunosuppressive DC. These DC, by virtue of
their CD8alpha- CD11c? CD11b? surface phenotype,
resemble previously reported immunosuppressive DC
[81–83]. This observation is of obvious clinical signifi-
cance especially as immunosuppressive DC are now in the
investigational stage of clinical study to treat autoimmunity
and have long been considered as cell therapeutics to
facilitate allograft survival [33]. PI3K inhibition during the
process of DC generation, in our experience, was not
associated with apoptosis or impaired cell survival at levels
higher than routinely observed in generating DC from bone
marrow progenitors, although some reports indicate that
DC exposure to PI3K inhibitors promotes apoptosis
[126–129]. This may reflect species-specific effects or that
PI3K inhibition during DC generation does not affect cell
survival. Our data also demonstrate that it is possible to
override a PI3K-impaired, immunosuppressive state in DC
by provision of a TLR signal, in our case-CpG oligonu-
cleotides acting through TLR9. Furthermore, we show that
the timing of PI3K inhibition is important in dictating the
outcome of DC phenotype. When PI3K is inhibited in a
Fig. 6 TLR9 agonist CpG ODN 1826 overrides the effects of LY-
294002 in generating immunosuppressive DC from bone marrow
progenitors. a Shown are the FACS quadrants in which cells with
CD11c and CD11b surface expression were identified, forward versus
side scatter and historams showing the levels and frequency of
CD8alpha- cells inside a CD11c? CD11b? population. The tables
summarise the frequency of CD11c? CD11b? cells as a percentage
of total cells, CD8alpha- CD11c? CD11b? cells as a percentage of
total cells as well as the MFI of class I and class II MHC on CD11c?
CD11b? cells. Data are shown for the phenotypes of day 6 DC
generated under control, LY-294002 (LY), ODN 1826 and combined
LY/ODN 1826 conditions. The measurements indicate the mean ±
SEM of quadruplicate independent cultures. b DC were generated in
GM-CSF/IL-4 in the presence or absence of ODN 1826 and the
combination of ODN 1826 and LY-294002. At the end of the DC
generation, LY-294002 and ODN 1826 were washed off, and the cells
were further washed extensively. The DC were collected on day 7 and
added to allogeneic splenic T-cells in vitro. At the end of the 5 day
MLR, the cultures were pulsed with BrdU, and after an overnight
incubation, the frequency of BrdU? cells (representing proliferating
cell frequency) was measured by FACS. The graph shows the
frequency of proliferating cells as a stimulation index (SI). The SI was
calculated by dividing the proliferation of T-cells in the different co-
cultures by background proliferation. Proliferation observed in
cultures of T-cells only was considered to be the background level
and assigned a value of 1. The bars represent the means, and the error
bars represent the SEM of quadruplicate wells. P \ 0.05 by ANOVA
(one-tailed) comparing proliferation of allogeneic T-cells in co-
culture with control-generated DC, ODN 1826-generated DC and LY-
294002-generated DC. c The culture supernatants from the day 5
allogeneic MLR were collected, and the cytokine profiles were
identified along with the measurement of concentrations of the
detectable cytokines. IL-6 and IL-1 beta were detected only in the
MLR supernatants of co-cultures with ODN 1826-generated DC and
allogeneic T-cells and ODN 1826/LY-294002-generated DC co-
cultures. The bars represent the means of the cytokine concentrations
and the error bars the SEM of quadruplicate wells. P \ 0.05 by
ANOVA (one-tailed) comparing cytokine concentrations from cul-
tures of allogeneic T-cells in co-culture with control-generated DC,
ODN 1826-generated DC, and LY-294002-generated DC
b
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sustained manner during the generation of DC, immuno-
suppressive cells develop. PI3K inhibition resulted in DC
that expressed low levels of CD86 and CD40 and
production of lower concentrations of proinflammatory
cytokines in vitro. Furthermore, generation of DC in the
presence of the PI3K inhibitor resulted in substantially
Fig. 7 Phosphorylation patterns of Akt, p38, and nuclear GSK-3 beta
as well as nuclear levels of NF-kappaB p65 in control- and LY-
294002-generated DC in vitro. DC generated from murine bone
progenitors under standard GM-CSF/IL-4 conditions with or without
the addition of LY-294002 throughout the generation process were
collected on day 7. The cells were processed to obtain a cytosolic or
nuclear fraction. The proteins in the fractions were resolved
electrophoretically in SDS–PAGE gels, and the specific phosphopro-
teins were identified in western blots using phospho-specific
antibodies. As controls, antibodies specific for the unphosphorylated
proteins were used to probe parallel blots. The data are representative
of two DC preparations under each condition. a Phosphorylated Akt is
undetectable in LY-294-002-generated DC at all days of the
generation process in vitro (right-side panels) compared to the levels
of phospho-Akt in control-generated DC (left panels). The lower
panels show the total levels of Akt in the DC at each day of the
generation process. b Phosphorylated p38 levels increase to reach an
apparent steady amount by day 3 in LY-294002-generated DC (right-
side panel) compared to control-generated DC (left-side panel) which
exhibit a sharp increase in phospho-p38 on day 3 and return to day 1
levels between day 4 and the day of DC collection for analysis. The
lower panels show the total levels of p38 in the DC at each day of the
generation process. c NF-kappaB p65 is found at lower amounts in the
nuclei of LY-294002-generated DC compared to control-generated
DC. NF-kappaB p65 is not detectable on day 1 in DC differentiation
in GM-CSF/IL-4, but is evident on day 2 and is stable at that level for
every remaining day (left-side panel). In contrast, LY-294002
exposure of the differentiating DC elicits nuclear p65 accumulation
on day 1 which drops on day 3 to a stably similar level between days
4 and 7 (right-side panel). d LY-294002 prevents the downregulation
of nuclear phospho-GSK-3 beta in DC differentiating in vitro from
GM-CSF/IL-4-cultured murine bone marrow progenitors. In contrast
to LY-294002-generated DC (right-side panel), nuclear levels of
phospho-GSK-3 beta exhibit a dramatic decrease starting on day 4 to
barely detectable levels by the end of the culture period (left-side
panel). Phospho-GSK-3 beta levels appear stable across all days of
the DC generation process in the presence of LY-294002 (right-side
panel). The lower panels show the total levels of GSK-3 beta in the
DC at each day of the generation process
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lower levels of class I and class II MHC on the surface.
Additionally, these DC significantly decreased the fre-
quency of CD4? CD25- T-cells in vitro, possibly due to
poor MHC-dependent antigen presentation, poor co-stim-
ulation, and an absence of potent immunostimulatory
cytokines. In contrast, PI3K inhibition initiated in fully
differentiated DC was slightly immunostimulatory.
Although we did not exhaustively determine the levels
of all possible DC surface markers, our interest in immu-
noregulatory DC prompted us to explore more general
phenotypes. LY-294002-generated DC segregated into two
distinguishable populations compared to control-generated
DC. Control-generated DC were more heterogeneous in
terms of CD11c? CD11b? cell prevalence, whereas LY-
294002-generated DC diverged into minor constituent
CD11c- CD11b? and a predominant CD11c? CD11b?
population. Although a Gaussian distribution of class I and
class II MHC? cells was evident in LY-294002-generated
DC compared to control-generated DC, the levels of class I
and class II MHC on a per cell basis were significantly
lower in LY-294002-generated DC.
We noted that LY-294002-generated DC also segregate
predominantly into a CD11c? CD8alpha- population,
whereas control-generated DC represented a heterogeneous
population of CD11c? CD8alpha? and CD11c? CD8al-
pha- cells. LY-294002-generated DC shifted CD8alpha-
cells into a CD11c? CD11bHIGH/INTERMEDIATE population
compared to control-generated DC although the shift
toward a CD11bINTERMEDIATE state in LY-294002-gener-
ated CD11c? DC resulted in co-segregation of the majority
of CD8alpha- cells into this CD11c? CD11bINTERMEDIATE
population.
Even as the LY-294002-generated DC express a
CD8alpha- CD11c? CD11b? phenotype resembling
already-described immunosuppressive DC [81–83], they
did not promote Foxp3? Treg expansion unlike previous
reports [81, 82] although the levels of Foxp3 in CD4?
CD25? Foxp3? cells were increased on a per cell basis.
We also observed a minor population of CD11c- class I
MHCLOW cells generated from bone marrow progenitors in
the presence of LY-294002 which could represent an
additional regulatory cell type [83]. An additional feature
of the LY-294002-generated DC was their production, in
vitro, of GM-CSF. This cytokine has been reported by
others to increase the frequency of CD8alpha- CD11c?
CD11b? DC which express TGFbeta and IL-10 [81].
However, unlike those reports, we were unable to detect
TGFbeta or IL-10 in the supernatants of the LY-294002-
generated DC. It is possible that our immunosuppressive
DC represent a population of metastable DC that overlap
with the developmental stage and capacity of other previ-
ously characterised CD8alpha- DC, although distinct in
other features and activities.
We propose that PI3K serves as a checkpoint during DC
differentiation whose activity level can balance a shift
between an immunosuppressive versus an immunostimu-
latory phenotype especially early during DC differentiation
from monocyte progenitors, or in immature DC in vivo.
We discovered a considerable level of complexity as we
examined PI3K-relevant intracellular signaling in murine
bone marrow progenitors differentiating toward DC in vitro
in conditions of sustained PI3K inhibition with or without
sustained TLR9 signaling using a well-defined CpG oli-
gonucleotide. We confirmed PI3K inhibition by the
observation that Akt phosphorylation was absent at all days
during DC generation. Concurrently, we observed that in
PI3K-impaired DC, p38 phosphorylation was elevated.
PI3K is known to act on the p38 signaling pathway
upstream of p38 itself, quite possibly at the level of MKK3/
6 [16, 130]. One possible interpretation of our data could
be that PI3K would act on kinases upstream of p38 and
would thus act as a negative regulator of p38 phosphory-
lation. PI3K inhibition would therefore be permissive for
p38 phosphorylation. In fact, Berra et al. [131] presented
data suggesting that PI3K/Akt signaling antagonises p38
activation and subsequent apoptosis induction. Similarly,
in endothelial cells, VEGF activates the PI3K/Akt signal-
ing pathway to prevent apoptosis by downregulation of the
p38 signaling pathway [132]. Mechanistically, Akt has
been shown to form a stable complex with p38 in human
neutrophils [130]. In light of our data and these observa-
tions, it is possible that PI3K signals to the p38 pathway to
maintain low levels of p38 phosphorylation and that with
DC differentiation, PI3K signaling via Akt decreases, act-
ing in a permissive manner to facilitate increased p38
phosphorylation. Our data (Figs. 7a, b) are potentially
compatible with such a mechanism, especially since PI3K
inhibition results in significant increases in the levels of
phospho-p38 (Fig. 7b). As such, we propose that during
DC differentiation in vitro, in the presence of IL-4 and
GM-CSF, p38 activity conditions the cells to maintain an
immature state (p38 phosphorylation is evident in day 1
bone marrow progenitors differentiating toward DC;
Fig. 7b). PI3K regulates the phosphorylation of p38
(maintains low phospho-p38 levels), and therefore, PI3K,
as a potential regulator, could define the balance between
immunosuppressive versus immunostimulatory DC. When
PI3K activity is impaired, p38 activity increases and this
further shifts the balance of the DC phenotype toward cells
with low levels of CD40 and CD86 cell surface co-stim-
ulatory proteins as well as cells that produce low concen-
trations of proinflammatory cytokines. What the signals are
that maintain p38 in a phosphorylated state in immature
DC and how these relate to low levels of CD40 and CD86
costimulatory proteins at the cell surface as well as low to
absent proinflammatory cytokine production is unclear,
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although NF-kappaB p65 is detectable in the nucleus
as early as day 2 during the generation of DC and at a
sustained levels from that time until DC harvest (Fig. 7c).
NF-kappaB is known to transactivate the expression of
CD86, CD40 and a number of proinflammatory cytokines
[133, 134].
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Another potential level of signaling control in DC-
generated in vitro which could determine the balance
between immunosuppressive versus immunostimulatory
DC rests with GSK-3 beta. In the unphosphorylated state,
GSK-3 beta acts as a transcriptional repressor [115, 118]
and has been shown to prevent the expression of IL-10
[112, 115]. When phosphorylated, GSK-3 beta cannot
inhibit CREB-dependent expression of IL-10 [112, 115]
partly due to the decreased ability of NF-kappaB to interact
with CREB and inhibit its transcriptional activity. PI3K has
been proposed as one of the signaling pathways that can
alter GSK-3 beta phosphorylation and activity [112, 115].
For example, Martin et al. [100, 112] have suggested that
PI3K-dependent Akt can phosphorylate GSK-3 beta in
response to TLR signaling and therefore downregulate its
transcriptional repressive effects resulting in the production
of IL-10 in peripheral blood mononuclear cells [100, 112].
Our data are consistent with such a PI3K-sensitive outcome
on GSK-3 beta in DC-generated in vitro since DC gener-
ated under control conditions exhibit a steady decrease in
phospho-GSK-3 beta (Fig. 7d) while DC generated under
conditions of PI3K inhibition exhibit a relatively constant
level of phospho-GSK-3 beta at levels higher than control
DC (Fig. 7d). GSK-3 beta could therefore be another target
of PI3K during DC generation that together with p38 could
be part of a PI3K-controlled circuit of DC differentiation
shifting the balance along an immunosuppressive or
immunostimulatory pathway. In support of such a mecha-
nism, we also show that DC generated under control con-
ditions exhibit a steady level of nuclear NF-kappaB p65 at
all days in culture, whereas PI3K-impaired DC exhibit a
detectable, but significantly lower nuclear accumulation of
NF-kappaB p65, an observation in line with a potential
GSK-3 beta-mediated mechanism of transcriptional mod-
ulation [135–137].
Our data indicate that sustained TLR9 signaling in dif-
ferentiating DC can override the effect of PI3K inhibition
on allostimulation (Fig. 6b). We also show that sustained
TLR9 signaling in the presence of LY-294002 in differ-
entiating DC results in a very low level of phospho-p38 and
nuclear phospho-GSK-3 beta, although the significant
decline (by day 3) in GSK-3 beta protein levels (shown in
Fig. 8e) is suggestive of degradation of GSK-3 beta and/or
nuclear exclusion of the protein rather than a well-defined
change in its phosphorylation state. TLR9 stimulation in
the absence of any other modifier in DC often results in the
phosphorylation of p38 and, as indicated above, in the
phosphorylation of GSK-3 beta. That PI3K inhibition
downregulates phosphorylation of p38 in the presence of a
TLR9 agonist suggests that PI3K plays a more significant
role in TLR9 signaling on the p38 pathway in DC than
originally considered [138–140] and that the interplay
between PI3K and p38, largely defined by PI3K activity,
could determine the outcome of DC differentiation or
balance toward an immunosuppressive or an immuno-
stimulatory state. Such a possibility is supported by our
finding that nuclear levels of phospho-GSK-3 beta are
significantly reduced in DC generated in the presence of
LY-294002 and ODN1826 (Fig. 8e).
It is interesting that PI3K inhibition during the DC
generation process from bone marrow progenitors in GM-
CSF and IL-4 promotes immunosuppressive DC, whereas
inhibition initiated in post-generated DC (i.e. LY-294002
addition on day 6 of the DC cultures) has a slight immu-
nostimulatory effect (compare Fig. 6b with Fig. 2). This
suggests that PI3K may play a regulatory role during DC
development and differentiation, but that in differentiated
cells, other signaling pathways override and/or are more
instrumental in conferring a functional phenotype to DC.
In sum, it is evident that the signaling components and
their regulation during the process of DC generation from
bone marrow progenitors of mice are complex. We antic-
ipate a similar situation for human DC. Our data suggest
that PI3K could be one of a series of important regulators
that determine the degree of DC immunocompetence and
Fig. 8 Phosphorylation patterns of Akt, p38, and nuclear GSK-3 beta
in DC generated from murine bone marrow progenitors in the
coninuous presence of an immunostimulatory CpG oligodeoxyribo-
nucleotide (ODN 1826) with or without LY-294002. DC generated
from murine bone progenitors under standard GM-CSF/IL-4 condi-
tions, with or without the addition of LY-294002 and/or ODN 1826
throughout the generation process, were collected on day 7. The cells
were processed to obtain a cytosolic or nuclear fraction. The proteins
in the fractions were resolved electrophoretically in SDS–PAGE gels,
and the specific phosphoproteins were identified in western blots
using phospho-specific antibodies. As controls, antibodies specific for
the unphosphorylated proteins were used to probe parallel blots. The
data are representative of two DC preparations under each condition.
a No differences in the level of phospho-Akt at all days in control- or
ODN 1826-generated DC with the exception of undetectable
phospho-Akt on day 7 of ODN 1826-generated DC (right-side upper
panel). The lower panels indicate phospho-p38 at all days of
generating DC. A significant increase in the level of phospho p38 is
apparent on day 3 in control-generated DC (lower left panels), but
otherwise, there is no clear difference in the phospho-p38 content of
control- versus LY-294002-generated DC (lower panels). b ODN
1826-generated DC exhibit detectable levels of nuclear phospho-
GSK-3 beta between days 2 and 6 (right-side panel) in contrast to
control-generated DC where phospho-GSK-3 beta becomes undetect-
able from day 4 onward. c Phospho-Akt is weakly detectable in DC
generated in the co-presence of LY-294002 and ODN 1826 (right-
side panel) compared to control-generated DC (left-side panel).
d Phospho-p38 is detectable on days 1 and 2 in DC generated in the
co-presence of LY-294002 and ODN 1826 (right-side panel)
compared to control-generated DC (left-side panel) where its level
is prominent on day 3 but returns to a stable level equal to that of days
1–2 for the remainder of the culture period (days 4–7). e A low, but
steady level of nuclear phospho-GSK-3 beta is evident across all days
of culture in DC generated in the co-presence of LY-294002 and
ODN 1826 (right-side panel) compared to control-generated DC (left-
side panel) where the phosphoprotein becomes barely detectable
starting on day 4
b
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Fig. 9 The addition of LY-294002 with or without ODN 1826
beginning at the time following DC generation results in cells that
exhibit immunostimulatory phenotype in vitro. DC were generated by
the standard GM-CSF/IL-4 method and on day 6, LY-294002 or ODN
1826 alone, or the combination were added to the generated DC for an
overnight incubation. The cells and supernatant were collected and
subsequently used in MLR and cytokine profiling. a LY-294002
addition to post-generated DC (i.e. LY-294002 was added at the end
of the 6-day DC generation) confers potent immunostimulatory
capacity to the cells in allogeneic MLR. An equal number of LY-
294002 post-generated DC were added to allogeneic splenic T-cells in
vitro for a standard five-day MLR. At the end of the 5 day MLR, the
cultures were pulsed with BrdU, and after an overnight incubation,
the frequency of BrdU? cells (representing proliferating cell
frequency) was measured by FACS. The graph shows the frequency
of proliferating cells as a stimulation index (SI). The SI was
calculated by dividing the proliferation of T-cells in the different co-
cultures by background proliferation. Proliferation observed in
cultures of T-cells only was considered to be the background level
and assigned a value of 1. The bars represent the means, and the error
bars represent the SEM of quintuplicate wells. P \ 0.05 by ANOVA
(one-tailed) comparing proliferation of allogeneic T-cells in co-
culture with LY-294002-post-generated DC. b LY-294002 addition to
post-generated DC results in immunostimulatory DC that elicit TNF-
alpha production by T-cells in MLR in vitro. The supernatants from
the allogeneic MLR were collected and screened for the cytokine
profile. TNF-alpha was the only consistently detectable cytokine in all
experiments. The bars represent the concentration of TNF-alpha as
measured by Luminex assay of the MLR supernatants and the error
bars the SEM of quintuplicate wells. P \ 0.05 (Student’s t test, one-
tailed). c Co-treatment of post-generated DC with LY-294002 and
ODN 1826 results in DC with more potent allostimulatory capacity
than post-generated DC treated with only one or the other agent. An
equal number of LY-294002/ODN 1826 co-treated post-generated
DC were added to allogeneic splenic T-cells in vitro for a standard
five-day MLR. For comparison, we repeated the experiment where
additional wells included post-generated DC treated only with ODN
1826 or LY-294002. At the end of the 5 day MLR, the cultures were
pulsed with BrdU, and after an overnight incubation, the frequency of
BrdU? cells (representing proliferating cell frequency) was measured
by FACS. The graph shows the frequency of proliferating cells as a
stimulation index (SI). The SI was calculated by dividing the
proliferation of T-cells in the different co-cultures by background
proliferation. Proliferation observed in cultures of T-cells only was
considered to be the background level and assigned a value of 1. The
bars represent the means, and the error bars represent the SEM of
quintuplicate wells. Statistically relevant differences in proliferation
are indicated with asterisks above the bars (ANOVA, one-tailed).
d Co-treatment of post-generated DC with LY-294002 and ODN
1826 yields DC that elicit IL-13, IL-6, and IL-12p70 in vitro in
allogeneic MLR, but not TNF-alpha. The supernatants from the
allogeneic MLR illustrated in c were collected and screened for the
cytokine profile. Unlike the previous experiment, TNF-alpha was
undetectable. The consistently detectable cytokines in all experiments
were IL-13, IL-6, and IL-12p70. The bars represent the concentration
of the cytokines as measured by Luminex assay of the MLR
supernatants and the error bars the SEM of quintuplicate wells
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that the modulation of PI3K could shift the differentiation of
monocyte progenitors of DC to either immunosuppressive or
immunostimulatory DC. Although PI3K could serve the role
of such a regulator during DC generation (and perhaps DC
maturation in vivo), PI3K appears to be complementary to
other molecular pathways that confer a stimulatory pheno-
type in differentiated DC. We hypothesise that, although one
can generate immunosuppressive and immunostimulatory
DC by PI3K modulation during the cell generation/differ-
entiation stage, once DC are fully differentiated from
monocytic progenitors, PI3K modulation may play a less
important role, especially since impairment of PI3K at the
end of the DC generation stage promotes stimulatory DC.
These observations are important given the existing clinical
applications of DC-based immunostimulatory vaccines and
the interest in using autologous DC to treat autoimmunity
and to facilitate allotransplantation.
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